c-LEcta

About:

c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets.

Website: https://www.c-lecta.com

Twitter/X: clecta

Top Investors: HTGF | High-Tech Gruenderfonds, Capricorn Partners, EASME - EU Executive Agency for SMEs, bm-t beteiligungsmanagement thuringen, SHS Capital

Description:

c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets such as food and pharmaceutical. It develops, manufactures, and commercializes application-oriented enzyme variants either as its own product or in cooperative development with industry partners. c-LEcta offers DENARASE, a genetically engineered endonuclease used in biotechnology for the quantitative removal of nucleic acids and viscosity reduction; and CalB Immo Plus, a hydrophobic immobilized CalB preparation. Marc Struhalla and Thomas Greiner-Stöffele founded it in 2004, with its headquarters in Leipzig in Germany.